Indolent Lymphoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Indolent Lymphoma - Pipeline Review, H2 2016

Indolent Lymphoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Indolent Lymphoma - Pipeline Review, H2 2016
Published Aug 10, 2016
213 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Indolent Lymphoma - Pipeline Review, H2 2016, provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8340IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Indolent Lymphoma Overview101
Therapeutics Development111
  Pipeline Products for Indolent Lymphoma Overview111
Indolent Lymphoma Therapeutics under Development by Companies122
Indolent Lymphoma Pipeline Products Glance142
  Late Stage Products141
  Clinical Stage Products151
Indolent Lymphoma Products under Development by Companies162
Indolent Lymphoma Companies Involved in Therapeutics Development1823
  AbbVie Inc181
  Affimed GmbH191
  Altor BioScience Corporation201
  Amgen Inc.211
  Astellas Pharma Inc.221
  Bayer AG231
  Boehringer Ingelheim GmbH241
  Bristol-Myers Squibb Company251
  Celgene Corporation261
  Eli Lilly and Company271
  F. Hoffmann-La Roche Ltd.281
  Gilead Sciences, Inc.291
  Incyte Corporation301
  Infinity Pharmaceuticals, Inc.311
  Juno Therapeutics Inc.321
  MedImmune, LLC331
  Merck &Co., Inc.341
  Merck KGaA351
  Millennium Pharmaceuticals Inc361
  MorphoSys AG371
  Novartis AG381
  Seattle Genetics, Inc.391
  Trillium Therapeutics Inc.401
Indolent Lymphoma Therapeutics Assessment4112
  Assessment by Monotherapy Products411
  Assessment by Combination Products421
  Assessment by Target433
  Assessment by Mechanism of Action463
  Assessment by Route of Administration492
  Assessment by Molecule Type512
Drug Profiles53147
  AFM-11 Drug Profile531
  ALT-803 Drug Profile543
  bendamustine hydrochloride Drug Profile573
  BI-836826 Drug Profile601
  blinatumomab Drug Profile618
  BMS-986016 Drug Profile692
  BTH-1677 Drug Profile7111
  CC-122 Drug Profile822
  copanlisib hydrochloride Drug Profile844
  DI-B4 Drug Profile881
  duvelisib Drug Profile8911
  entospletinib Drug Profile1002
  ibrutinib Drug Profile10225
  INCB-40093 Drug Profile1271
  INCB-50465 Drug Profile1281
  inebilizumab Drug Profile1292
  inebilizumab + MEDI-0680 Drug Profile1311
  itacitinib adipate Drug Profile1323
  JCAR-014 Drug Profile1353
  JCAR-015 Drug Profile1385
  JCAR-017 Drug Profile1433
  lenalidomide Drug Profile14614
  LY-3023414 Drug Profile1602
  MOR-208 Drug Profile1625
  obinutuzumab Drug Profile1677
  ofatumumab Drug Profile1748
  SEA-CD40 Drug Profile1821
  TAK-659 Drug Profile1831
  TTI-621 Drug Profile1843
  venetoclax Drug Profile1879
  vorinostat Drug Profile1964
Indolent Lymphoma Dormant Projects2002
Indolent Lymphoma Discontinued Products2021
Indolent Lymphoma Product Development Milestones2039
  Featured News &Press Releases2031
    Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society2031
    Nov 30, 2015: New Data from Bayer s Portfolio in Oncology to be Presented at ASH 20152031
    Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting2031
    Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG2041
    Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH2042
    Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R2061
    Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting2071
    Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH)2082
    Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH2102
Appendix2122
  Methodology2121
  Coverage2121
  Secondary Research2121
  Primary Research2121
  Expert Panel Validation2121
  Contact Us2121
  Disclaimer2131

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Indolent Lymphoma - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Indolent-Lymphoma-Pipeline-Review-H2-2016-2088-16348>
  
APA:
Global Markets Direct - Market Research. (2016). Indolent Lymphoma - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Indolent-Lymphoma-Pipeline-Review-H2-2016-2088-16348>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.